CPHI

Business Context and Reporting Period

Company: China Pharma Holdings, Inc. (CPHI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Operations: The Company operates through its wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., in the People's Republic of China (PRC). It develops, manufactures, and markets pharmaceutical products, including injectables, tablets, and capsules. The Company is classified as a "smaller reporting company" and a "non-accelerated filer."

Key Financial Metrics

Liquidity & Debt: Current liabilities ($7.27M) exceed current assets ($2.00M) by approximately $5.3 million. The Company holds $1.47M in borrowings from related parties (primarily the CEO) and $1.93M in current lines of credit. Cash flow from operating activities was negative $55,292 for the quarter.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 13.4% to $0.98M, primarily due to reduced sales of Anti-Viral/Infection products (down 43%) as competitors entered centralized procurement programs. Conversely, CNS/Cerebral & Cardio Vascular sales increased 50% due to successful bids in centralized procurement.
• Gross Margin Improvement: The Company shifted from a gross loss of $0.14M in Q1 2025 to a gross profit of $0.29M in Q1 2026. This was driven by lower depreciation expenses as certain property and equipment became fully depreciated.
• Increased Operating Expenses: General and Administrative (G&A) expenses surged 142% to $1.23M. This increase is attributed to the amortization of five new patented technologies acquired in late 2025.
• Intangible Assets Expansion: Total intangible assets increased from $24.1M to $38.7M following the acquisition of two new invention patents (Topiroxostat Nanoemulsion and Prinsepia Utilis Esterol Sublingual Tablets) valued at approximately $15M, paid for via stock issuance.
• Share Count Increase: Outstanding shares increased from 15.5M to 40.5M due to the issuance of 25M shares to fund the acquisition of intangible assets.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has disclosed substantial doubt about the Company's ability to continue as a going concern within one year. This is due to an accumulated deficit of $48.4M, recurring net losses, and a working capital deficit. The Company relies on advances from the CEO and potential strategic alternatives to fund operations.
• Strategic Initiatives: Management plans to enhance advance payment sales models, strengthen accounts receivable collection, and explore strategic alternatives for nutrition products. Cost reduction measures include consolidating procurement, optimizing production cycles, and focusing marketing on high-return channels.
• Regulatory Environment: The Company faces challenges with China's Centralized Procurement (CP) programs, which have reduced drug prices. Products must pass consistency evaluations to participate. The Company is proceeding cautiously with new evaluations based on ROI.
• Internal Controls: The Company disclosed a material weakness in internal controls over financial reporting due to a lack of personnel knowledgeable in U.S. GAAP. Management concluded disclosure controls were not effective as of March 31, 2026.
• Concentration Risk: Two customers accounted for 31.9% of sales, and two suppliers accounted for 71.6% of raw material purchases. Four products accounted for 86.3% of total revenue.

Investor Verification Checklist

• Going Concern Status: Verify the feasibility of management's cost-cutting plans and the sustainability of related-party funding (CEO advances).
• Intangible Asset Valuation: Review the valuation and amortization schedules of the $15M in patents acquired via stock issuance in Q1 2026.
• Centralized Procurement Impact: Monitor the progress of consistency evaluations for key products to determine eligibility for future CP bids.
• Internal Control Remediation: Assess the timeline and effectiveness of hiring U.S. GAAP-compliant accounting personnel to address the material weakness.
• Cash Burn Rate: Track monthly cash outflows against the $168k cash balance to determine the runway before additional financing is required.